$CRVO News

HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target

HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target

CervoMed Completes Enrollment In Phase 2A Study Of Neflamapimod For nfvPPA, Type Of Frontotemporal Dementia; First Biomarker Data Expected In Early Q4 Of 2026 And The First Clinical Data In Q1 2027

CervoMed Files Prospectus Related To Offer And Resale Of 10.08M Shares Of Common Stock By Selling Stockholders

CervoMed Agreed To Raise $10M in Direct Stock Offering Of 2.5M Shares At $4/Share, Plans to Use Stock Sale Proceeds for Working Capital

CervoMed Announces $10M Registered Direct Offering Of 2.5M Shares At $4/Share To Fund Working Capital And General Corporate Purposes

CervoMed Receives U.S. Patent For Its Neflamapimod Drug Candidate For The Treatment Of Dementia With Lewy Bodies

CORRECTION: Reported June 15, 2026: CervoMed Form4 Filing Shows Director Joshua S. Boger Acquired ~2.87M Share-Equivalent Position Via $3.14/Unit Private Placement (955,414 Shares Plus Matching Series B and C Warrants); Holds 20% Position As Of June 11, 2026

CervoMed Announces Private Placement With Expected Gross Proceeds Of ~$10.5M; Will Extend Cash Runway Into Q2 2027

CervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates

CervoMed Q1 EPS $(0.86) Misses $(0.78) Estimate

Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates

IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates

HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target

CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies

CervoMed Presents Data On Neflamapimod That May Increase Size, Enhance Function Of Basal Forebrain In Participants With Dementia With Lewy Bodies

CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting

CervoMed To Present Key Aspects Of Neflamapimod Clinical Program At 2026 Lewy Body Dementia Association Annual Meeting, Including Updates On Clinical Findings, Global Regulatory Alignment, And Finalized Phase 3 Trial Design In DLB

CervoMed (CRVO)’s Q4 Results Feature Advancements in Its Neflamapimod Program for Dementia Lewy Bodies (DLB)

CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod’s Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer’s Disease Co-Pathology